Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Abroad (travel likely)RecruitingPHASE1
Conditions
Multiple Sclerosis (MS) · Neuromyelitis Optica Spectrum Disorder (NMOSD) · Autoimmune Encephalitis (AE) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Myasthenia Gravis (MG) · Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD) · Idiopathic Inflammatory Myopathies (IIM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Study coordinator (Daishi Tian)Contact: Principal Investigator (Daishi Tian)Contact: Principal Investigator (Chuan Qin)
Study leads
Daishi Tian
Principal Investigator
Tongji Hospital
Chuan Qin
Principal Investigator
Tongji Hospital